Narrow Breadth Returns: Just 17% of S&P 500 Stocks Beat the Index Over the Past Month

Beneath a placid surface of record-high index levels, the U.S. equity market is flashing a familiar warning sign: leadership has collapsed back into a tiny cluster of mega-cap names. Over the past month, only roughly 17% of S&P 500 stocks have outperformed the index itself—among the lowest readings of the past ten years. Translation: the average stock is being left behind while a handful of giants do the heavy lifting. The contrast with how 2026 began is stark. Year-to-date, more than 60% of S&P 500 companies are still beating the index, and Q1 saw 57.8% of stocks outperform—a pace that, if sustained, would have marked the broadest market since 2009. That early broadening has since reversed. Recent weeks show concentration creeping higher again, with gains funneling into artificial-intelligence and energy-related names while the rest of the market stalls. Participation metrics confirm the thinning. Constituents trading above their 50-day moving average have slipped to roughly 52%, placing breadth in just the 36th percentile of its historical range—below the midpoint and well off levels typical of healthy, durable rallies. Mid-month checks showed only about 50% of stocks above their 200-day average. In short, many companies are lagging not just the index, but their own trend lines. The structural backdrop magnifies the risk. The top 10 names reached a record 40.7% of index weight in 2025, with the 'Magnificent Seven'—Nvidia, Microsoft, Apple, Amazon, Alphabet, Meta and Tesla—accounting for the bulk of recent earnings growth. Nvidia's dominance in AI accelerators has made it a single point of outsized influence on sentiment. When breadth narrows like this, the index becomes increasingly hostage to a few earnings reports. Why it matters: narrow breadth has historically preceded periods of elevated volatility and choppy returns, because fewer stocks supporting new highs means less margin for error if leadership stumbles. It does not guarantee a downturn—the 2023-2024 advance proved concentration can persist for quarters—but it raises the stakes. Equal-weight benchmarks lagging cap-weighted ones, a theme drawing attention this spring, underscore how reliant headline gains have become on the largest constituents. There are tentative offsets. Strategists point to early signs of fresh participation from mid-cap industrials, healthcare innovators and select consumer-discretionary names, and resilient AI-driven earnings continue to underpin valuations. A genuine broadening would be a meaningfully healthier signal than the current tape. For now, investors should treat the 17% figure as a caution flag rather than a sell trigger: the rally is intact but increasingly top-heavy, and the path forward hinges on whether breadth recovers or the generals keep marching alone. Sources: StreetStats, The Kobeissi Letter, RBC Wealth Management, Capital Group, Charles Schwab, First Trust.